NCT06191094Enrolling By InvitationPhase 4
A Randomized, Double-masked, Sham-controlled Study to Evaluate the Efficacy of Peri-operative Farcimab in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy
University of Colorado, Denver1 site in 1 country100 target enrollmentStarted: July 12, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Enrolling By Invitation
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Rates of post-operative vitreous hemorrhage
Study Overview
Brief Summary
In this phase IV, randomized, double-masked, sham-controlled study the investigators hope to determine the efficacy in peri-operative faricimab (Vabysmo) compared to sham in limiting complications from pars plana vitrectomy for diabetic vitreous hemorrhage with or without tractional retinal detachments.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Single (Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must meet the following criteria for study entry:
- •Signed Informed Consent Form
- •Age ≥ 18 years at time of signing Informed Consent Form
- •Ability to comply with the study protocol, in the investigator's judgment
- •For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined below:
- •Women must remain abstinent or use contraceptive methods with a failure rate of <1% per year during the treatment period and for 3 months after the final dose of the study drug.
- •A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).
- •Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
- •The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- •Ocular inclusion criteria for study eye:
- •● Patients diagnosed with non-clearing vitreous hemorrhage with or without tractional retinal detachment secondary to proliferative diabetic retinopathy and undergoing pars plana vitrectomy
Exclusion Criteria
- •Patients who meet any of the following general exclusion criteria will be excluded from study entry:
- •Any known hypersensitivity to any of the components in the faricimab injection
- •Any known hypersensitivity to any dilating eye drops, disinfectants (e.g., iodine), or any of the anesthetics and antimicrobial preparations used during the study
- •History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, or historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the investigator
- •Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab Women of childbearing potential must have a negative urine pregnancy test result at baseline prior to initiation of dosing of faricimab/sham and a negative urine pregnancy test at post-op Week 1 prior to dosing of faricimab/sham
- •Ocular exclusion criteria for study eye:
- •Patients who meet any of the following exclusion criteria for the study eye will be excluded from study entry:
- •Any ocular anti-VEGF treatment within 3 months prior to Day 1 (Baseline) in the study eye
- •Vitreous hemorrhage or tractional retinal detachment suspected due to cause other than diabetic retinopathy
- •Any glaucoma surgery in the study eye prior to the Day 1 (Baseline) visit
- •History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy in study eye
- •Uncontrolled glaucoma (e.g., progressive loss of visual fields or defined as intraocular pressure (IOP) ≥25 mmHg at the Day 1 (Baseline) visit despite treatment with anti-glaucoma medication)
- •Any history of idiopathic, infectious, or noninfectious uveitis
- •Any current or history of ocular disease other than diabetic retinopathy that may confound assessment of the macula or affect central vision (e.g., age-related macular degeneration, retinal vein occlusion, angioid streaks, histoplasmosis, active or inactive cytomegalovirus retinitis, pathological myopia, retinal detachment, macular traction, retinal embolus, macular hole)
Arms & Interventions
Sham injection
Sham Comparator
Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The sham procedure mimics an intravitreal injection of faricimab except that the blunt end of an empty syringe is pressed against an anesthetized eye instead of a needle attached to a faricimab-filled syringe.
Intervention: sham treatment (Drug)
Faricimab injection
Experimental
Patients will be randomized 2:1 to receive either farcimab (6 mg from 0.05 mL of a 120 mg/mL) or sham injection. The 6-mg dose of faricimab will be administered by IVT at the study site to patients. A specified filter needle must be used for each dose preparation of faricimab according to the instructions provided in the Investigator's Brochure and package insert. No other material than specified should be used. Vials of faricimab drug product are for a single-dose only (one injection preparation per patient per eye). Vials used for one patient must not be used for any other patient. Partially used vials, remaining faricimab drug product, as well as administration material must not be reused.
Intervention: Faricimab Injection (Drug)
Outcomes
Primary Outcomes
Rates of post-operative vitreous hemorrhage
Time Frame: 6 months
Following treatment and surgery, the development of vitreous hemorrhage will be quantified and evaluated.
Secondary Outcomes
- BCVA outcomes(6 and 12 months)
- Rates of re-operation for non-clearing vitreous hemorrhage(6 and 12 months)
- Number of retinal breaks intra-operatively.(intra-operatively)
- Number of patients with intra-operative bleeding(intra-operatively)
- Duration of operative time.(intra-operatively)
- Number of endodiathermy use exchanges intra-operatively.(intra-operatively)
- Rate of post-operative rhegmatogenous or tractional retinal detachment.(Through study completion, an average of 1 year)
- Rate of post-operative epiretinal membrane formation.(Through study completion, an average of 1 year)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During RelapseMultiple SclerosisNCT00753792Germans Trias i Pujol Hospital49
Completed
Phase 4
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With ValbenazineTardive Dyskinesia (TD)NCT03698331Neurocrine Biosciences89
Active, not recruiting
Phase 1
Multicenter clinical trial to evaluate the efficacy of a preventive strategy against CMV infection in heart transplant patients, based on T cells responses.We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization of the preventión strategy. The drugs valganciclovir and ganciclovir will be used in seropositive patitens (IgG against CMV), not indicated in the data sheet but accepted as part of the habitual prophylaxis of heart transplant patient according to the clinical practice guidelines.MedDRA version: 20.0 Level: LLT Classification code 10058666 Term: Cytomegalovirus infection reactivation System Organ Class: 100000004862EUCTR2019-002233-11-ESDr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge188
Completed
Phase 4
Study Comparing Treatment With Alluzience vs Reconstituted ToxinGlabellar Frown LinesNCT05277337Galderma R&D150
Completed
Phase 4
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or FeetPsoriasisNCT00312026Genentech, Inc.75